Published online Mar 27, 2015. doi: 10.4254/wjh.v7.i3.532
Peer-review started: August 29, 2014
First decision: September 30, 2014
Revised: October 21, 2014
Accepted: December 16, 2014
Article in press: December 16, 2014
Published online: March 27, 2015
Core tip: In the liver transplant (LT) setting, graft loss due to hepatitis C virus (HCV) recurrence is a serious problem after LT. The former conventional treatment with pegylated interferon and ribavirin is unsatisfying, due to poor response rates and tolerability. With the first interferon-free regimens that are currently being approved for the treatment of patients with chronic HCV, 2014 marks the beginning of a new era of treatment options for HCV recurrence after LT. This review summarizes the current experience with and the expectations of the new direct-acting antiviral agents in the setting of LT.